Development of [225Ac]Ac-PSMA-I&T for Targeted Alpha Therapy According to GMP Guidelines for Treatment of mCRPC

Recently, promising results of the antitumor effects were observed in patients with metastatic castration-resistant prostate cancer treated with 177Lu-labeled PSMA-ligands. Radionuclide therapy efficacy may even be improved by using the alpha emitter Ac-225. Higher efficacy is claimed due to high li...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Pharmaceutics 2021-05, Vol.13 (5), p.715
Hauptverfasser:	Hooijman, Eline L., Chalashkan, Yozlem, Ling, Sui Wai, Kahyargil, Figen F., Segbers, Marcel, Bruchertseifer, Frank, Morgenstern, Alfred, Seimbille, Yann, Koolen, Stijn L. W., Brabander, Tessa, de Blois, Erik
Format:	Artikel
Sprache:	eng
Schlagworte:	Cancer therapies Ethanol Ligands Pharmacy Prostate cancer Quality control Radiation therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!